Logix Biosciences

Logix Biosciences is a pre-clinical pharmaceutical platform company targeting WHO-listed multidrug-resistant pathogens amid stalled development of new mechanisms. Three decades of broad global human use of its natural composition qualifies its FDA 505(b)(1) botanical pathway. Its proprietary platform composition, LBX242, is treated as a black box and protected by patent; the pre-clinical platform spans antibacterial, antiviral, and angiogenic fronts through a single patented engine.

Conventional antibiotics act on a single target site and select for resistance; by contrast, no evolutionary resistance has been observed across three decades of use of the composition. The company has a strategic agreement with Mayo Clinic.